# Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment

Source: https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/  
OnCo record `capillary-leak-syndrome-on-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A few cancer medicines can make the smallest blood vessels leaky, so fluid and protein seep out of the blood into the tissues. The signs are weight gain, swelling, breathlessness and low blood pressure. Teams watch weight, blood pressure and, for some of these medicines, a blood protein called albumin. If signs appear they pause the medicine and treat by that medicine's own rules.

## Summary

Capillary leak syndrome (CLS) is loss of protein-rich fluid from the circulation: hypoalbuminaemia, oedema and weight gain, hypotension, and in severe cases pulmonary oedema, shock and acute kidney injury. Among anticancer drugs with records here, tagraxofusp and aldesleukin carry boxed warnings for it, dinutuximab and dinutuximab beta list it as a warning, and gemcitabine's label tells prescribers to stop the drug for good.

The tagraxofusp label has the most detailed rules. Albumin must be at least 3.2 g/dL before the first dose; cycle 1 is given in hospital; vital signs, albumin, transaminases and creatinine are checked before every dose. During dosing, an albumin below 3.5 g/dL or a fall of 0.5 g/dL or more from the start of the cycle, or a weight gain of 1.5 kg or more over the previous day's pre-dose weight, means the dose is held and 25 g of intravenous albumin is given every 12 hours or more often; oedema, fluid overload or hypotension add methylprednisolone 1 mg/kg a day and active fluid and blood pressure management. The label reports CLS in 53% of 122 patients by a broad definition, a median onset of 4 days, and four deaths.

Dinutuximab (children with high-risk neuroblastoma) needs 10 mL/kg of 0.9% saline over an hour before each infusion, close blood pressure monitoring, interruption for moderate to severe CLS with restart at half rate, and permanent discontinuation if life-threatening CLS recurs. The EU label for dinutuximab beta says the leak usually develops within hours of starting treatment, with low blood pressure and a fast pulse reported after 2 to 12 hours, and stops the drug for good for recurrent or grade 4 CLS. Aldesleukin is given only in a hospital with an intensive care facility and is withheld when organ perfusion fails.

The sources pull in different directions on fluids: the dinutuximab label requires pre-hydration and the tagraxofusp label uses intravenous fluids for hypotension, while the review of anticancer drug-induced CLS says saline should be limited because it worsens oedema. None of the sources read cites a randomised trial of albumin, steroids or any fluid strategy for drug-induced CLS. The reader's own team's protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: capillary leak syndrome; CLS; vascular leak syndrome; systemic capillary leak; tagraxofusp capillary leak; Elzonris albumin monitoring; dinutuximab capillary leak; interleukin-2 capillary leak

## Connected records

- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Dinutuximab (ch14.18) / dinutuximab beta](https://onco.cc/drugs/dinutuximab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Tagraxofusp](https://onco.cc/drugs/tagraxofusp/)
- protocols: [Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids](https://onco.cc/protocols/crs-grading-and-management/), [Differentiation syndrome on IDH, FLT3 and menin inhibitors and on tretinoin or arsenic trioxide: recognition and treatment](https://onco.cc/protocols/differentiation-syndrome-recognition-and-treatment/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/), [Suspected febrile neutropenia (neutropenic sepsis): the first hour](https://onco.cc/protocols/febrile-neutropenia-first-hour/)

---
JSON: https://onco.cc/api/v1/entities/capillary-leak-syndrome-on-anticancer-drugs.json